{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["112(1)"],"submitter":["D'Incecco A"],"pubmed_abstract":["<h4>Background</h4>Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether PD-1/PD-L1 are differently expressed in oncogene-addicted NSCLC.<h4>Methods</h4>We analysed a cohort of 125 NSCLC patients, including 56 EGFR mutated, 29 KRAS mutated, 10 ALK translocated and 30 EGFR/KRAS/ALK wild type. PD-L1 and PD-1 expression were assessed by immunohistochemistry. All cases with moderate or strong staining (2+/3+) in >5% of tumour cells were considered as positive.<h4>Results</h4>PD-1 positive (+) was significantly associated with current smoking status (P=0.02) and with the presence of KRAS mutations (P=0.006), whereas PD-L1+ was significantly associated to adenocarcinoma histology (P=0.005) and with presence of EGFR mutations (P=0.001). In patients treated with EGFR tyrosine kinase inhibitors (N=95), sensitivity to gefitinib or erlotinib was higher in PD-L1+ vs PD-L1 negative in terms of the response rate (RR: P=0.01) time to progression (TTP: P<0.0001) and survival (OS: P=0.09), with no difference in PD1+ vs PD-1 negative. In the subset of 54 EGFR mutated patients, TTP was significantly longer in PD-L1+ than in PD-L1 negative (P=0.01).<h4>Conclusions</h4>PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC supporting further investigation of specific checkpoint inhibitors in combination with targeted therapies."],"journal":["British journal of cancer"],"pagination":["95-102"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4453606"],"repository":["biostudies-literature"],"pubmed_title":["PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients."],"pmcid":["PMC4453606"],"pubmed_authors":["Andreozzi M","Rossi E","Crino L","Tornillo L","Cappuzzo F","Coppi E","Incensati RM","Ludovini V","Salvini J","Capodanno A","Sani S","Fontanini G","Landi L","Chella A","Terracciano L","Filice ME","Tibaldi C","Minuti G","D'Incecco A"],"additional_accession":[]},"is_claimable":false,"name":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.","description":"<h4>Background</h4>Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether PD-1/PD-L1 are differently expressed in oncogene-addicted NSCLC.<h4>Methods</h4>We analysed a cohort of 125 NSCLC patients, including 56 EGFR mutated, 29 KRAS mutated, 10 ALK translocated and 30 EGFR/KRAS/ALK wild type. PD-L1 and PD-1 expression were assessed by immunohistochemistry. All cases with moderate or strong staining (2+/3+) in >5% of tumour cells were considered as positive.<h4>Results</h4>PD-1 positive (+) was significantly associated with current smoking status (P=0.02) and with the presence of KRAS mutations (P=0.006), whereas PD-L1+ was significantly associated to adenocarcinoma histology (P=0.005) and with presence of EGFR mutations (P=0.001). In patients treated with EGFR tyrosine kinase inhibitors (N=95), sensitivity to gefitinib or erlotinib was higher in PD-L1+ vs PD-L1 negative in terms of the response rate (RR: P=0.01) time to progression (TTP: P<0.0001) and survival (OS: P=0.09), with no difference in PD1+ vs PD-1 negative. In the subset of 54 EGFR mutated patients, TTP was significantly longer in PD-L1+ than in PD-L1 negative (P=0.01).<h4>Conclusions</h4>PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC supporting further investigation of specific checkpoint inhibitors in combination with targeted therapies.","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jan","modification":"2024-11-21T04:06:05.535Z","creation":"2019-03-27T01:52:41Z"},"accession":"S-EPMC4453606","cross_references":{"pubmed":["25349974"],"doi":["10.1038/bjc.2014.555"]}}